节点外围T细胞淋巴瘤的前线管理
1Centre for Lymphoid Cancer BC Cancer, Division of Medical Oncology, BC Cancer and University of British Columbia, Vancouver, BC, Canada.
概括
周围T细胞淋巴瘤 (PTCL) 是多样而罕见的,治疗进展有限. 像布伦图西马布维多丁 (brentuximab vedotin) 这样的新疗法对某些PTCL亚型有前途,而其他则需要进一步研究.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 淋巴瘤研究 淋巴瘤研究
背景情况:
- 周围T细胞淋巴瘤 (PTCL) 占非霍奇金淋巴瘤的10-15%,具有显著的异质性和超过30种亚型.
- 由于罕见性和疾病多样性,PTCL的治疗进展在历史上落后于B细胞淋巴瘤.
- 常见的结节PTCL亚型包括PTCL-not otherwise specified (NOS),阿纳塑性大细胞淋巴瘤 (ALCL) 和结节T毛囊辅助细胞淋巴瘤 (TFHL).
研究的目的:
- 审查当前的治疗环境和近期在对外围T细胞淋巴瘤 (PTCLs) 管理方面的进展.
- 突出基于分子分析和特定PTCL亚型的新兴个性化治疗策略.
- 讨论关于最佳前线治疗和巩固性干细胞移植的作用的持续辩论.
主要方法:
- 关于PTCL治疗的当前文献和临床试验数据的综述.
- 对不同PTCL亚型的治疗结果的分析,包括ALCL,TFHL和PTCL-NOS.
- 在PTCL管理中讨论新型治疗剂和分子向方法.
主要成果:
- 环胺,多克索鲁比辛,普雷德尼松和布伦图西马布维多丁 (CHP-BV) 是ALCL的新标准,证明了整体生存益处.
- TFHL淋巴瘤对表观遗传疗法表现出敏感性,促使其在前线环境中进行研究.
- PTCL-NOS的分子亚型 (例如,GATA3,TBX21) 正在出现,但治疗含义仍在调查中.
结论:
- 个性化治疗越来越适用于特定的PTCL亚型.
- 在ALCL以外的PTCL最佳前线治疗策略仍然是积极研究和辩论的领域.
- 需要进一步的研究来确定新药和巩固性自身干细胞移植在实现长期缓解中的作用.
更多相关视频
07:45Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
Published on: January 26, 2024
2.0K
07:39Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
Published on: January 7, 2019
12.3K
相关概念视频
Primary Lymphoid Organs
1.7K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
1.7K
Secondary Lymphoid Organs
1.7K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
1.7K
Lymphoid Cells and Tissues
1.3K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.3K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
